Search for a trial | Research with human participants

2 results

An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials (CONNEX-X).

Approved WMOPending

This study has been transitioned to CTIS with ID 2024-511560-93-00 check the CTIS register for the current data. The objective of this trial is to collect additional safety data.The further objective of this trial is to collect long-term efficacy…

A phase III randomized, double-blind, placebo-controlled, parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-2)

Approved WMOCompleted

The primary objective of this trial in CIAS is to assess the efficacy in improving cognitive impairment using MCCB in patients with schizophrenia treated for 26 weeks with Iclepertin 10mg as compared with placebo.